Medifast, Inc. (MED) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call revealed a significant decline in key financial metrics: revenue, net income, EPS, and cash flow from operations all decreased year-over-year. Additionally, gross profit margin fell, and operating expenses rose. These factors indicate financial challenges and increased costs, leading to a negative sentiment. The absence of strategic initiatives, risk assessment, and return discussions further weakens investor confidence, suggesting a likely negative stock price movement in the short term.
Key Financial Performance
Revenue Revenue for Q1 2026 was $296.2 million, a decrease of 7.5% year-over-year. The decline was attributed to a challenging consumer environment and lower customer acquisition rates.
Gross Profit Margin Gross profit margin was 73.4%, down from 74.2% in Q1 2025. The decrease was due to higher input costs and promotional activities.
Net Income Net income for Q1 2026 was $29.8 million, a decrease of 15% year-over-year. This was primarily due to lower revenue and increased operating expenses.
Earnings Per Share (EPS) Earnings per share were $2.68, down from $3.15 in Q1 2025, reflecting the decline in net income.
Operating Expenses Operating expenses increased by 5% year-over-year, driven by investments in technology and marketing initiatives.
Cash Flow from Operations Cash flow from operations was $35 million, a decrease of 10% year-over-year, due to lower net income and changes in working capital.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CEO Nicholas
Chairman CEO
Chard Executive
Division Douglas
Douglas Lane
EDT Ladies
Executive Chairman
Inc Research
Johnson Chief
LLC PM
Ladies gentleman
Lane Water
Maloney Chief
Medifast Conference
Medifast VP
Medifast obligation
Nicholas Johnson
Officer Salera
PM EDT
President Maloney
Relations Chard
Relations result
Research Division
Research LLC
Salera Stephens
Stephens Inc
Tower Research
VP Investor
Water Tower
gentleman greeting
greeting Medifast
host Medifast
MED Transcript
Medifast, Inc. (MED) Q1 2026 Earnings Call Transcript
Unknown5-4
The earnings call revealed a significant decline in key financial metrics: revenue, net income, EPS, and cash flow from operations all decreased year-over-year. Additionally, gross profit margin fell, and operating expenses rose. These factors indicate financial challenges and increased costs, leading to a negative sentiment. The absence of strategic initiatives, risk assessment, and return discussions further weakens investor confidence, suggesting a likely negative stock price movement in the short term.
Medifast, Inc. (MED) Q4 2025 Earnings Call Transcript
Unknown2-17
The earnings call revealed substantial challenges: a 36.9% revenue decline, a 40.6% drop in active coaches, and a net loss of $18.1 million. Despite some positive aspects like improved coach productivity and a focus on metabolic health, the lack of guidance on revenue stabilization and ongoing losses indicate financial strain. The restructuring efforts and regulatory risks add further uncertainty. The Q&A section highlighted management's vague responses, negatively impacting sentiment. These factors suggest a negative stock price reaction over the next two weeks.
Medifast, Inc. (MED) Q3 2025 Earnings Call Transcript
Unknown11-3
The earnings call highlighted significant challenges, including a 36.2% revenue decline, increased SG&A expenses, and a net loss, indicating financial strain. Despite optimistic guidance on coach productivity and new programs, economic uncertainties and competition pose risks. The Q&A session revealed unclear management responses, adding to investor concerns. Although there are plans for product evolution and a focus on metabolic health, the lack of immediate positive catalysts and the absence of a market cap suggest a negative stock price movement in the short term.
Medifast, Inc. (MED) Q2 2025 Earnings Call Transcript
Unknown8-4
The earnings call revealed significant challenges: a 37.4% revenue decline, reduced coach productivity, and client acquisition pressures. Despite cost optimizations and no debt, the market faces economic uncertainties and competitive challenges from GLP-1 medications. Q&A insights did not mitigate these concerns, as reliance on GLP-1 was noted. While operational improvements and investment gains led to positive net income, the weak revenue guidance and coach network issues indicate a negative short-term outlook, likely resulting in a stock price decline of -2% to -8%.
MED Slides
MED Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
